Overview

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Status:
Terminated
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
This is a two-part, open label, single-dose study that will evaluate the PK of tozadenant in subjects with different degrees of hepatic impairment to the PK of a single-dose of tozadenant in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Biotie Therapies Inc.
Collaborator:
Acorda Therapeutics